Baseline characteristics
| TCZ+MTX (N=277) | TCZ+PBO (N=276) | |
|---|---|---|
| Women, n (%) | 227 (81.9) | 217 (78.6) |
| Age (years), mean (SD) | 53.0 (13.4) | 53.6 (11.9) |
| Patients aged ≥65 years, n (%) | 53 (19.1) | 52 (18.8) |
| BMI, kg/m2, mean (SD) | 26.3 (5.20) | 26.5 (5.14) |
| Duration of RA, years, mean (SD) | 8.2 (8.0) | 8.3 (8.4) |
| Categorical duration of RA in years, n (%): | ||
| <2 | 51 (18.4) | 66 (23.9) |
| ≥2 to <5 | 76 (27.4) | 68 (24.6) |
| ≥6 to <10 | 66 (23.8) | 63 (22.8) |
| ≥10 | 84 (30.3) | 79 (28.6) |
| Swollen joint count, mean (SD) | 14.4 (8.9) | 15.3 (10.2) |
| Tender joint count, mean (SD) | 25.8 (13.9) | 26.6 (15.2) |
| DAS28–ESR, mean (SD) | 6.33 (0.98) | 6.36 (1.00) |
| HAQ–DI, mean (SD) | 1.46 (0.66) | 1.48 (0.60) |
| HAQ–DI <0.5, n (%) | 17 (6.2) | 14 (5.2) |
| Genant-modified Sharp score, mean (SD) | 30.4 (31.8) | 37.1 (40.5) |
| Methotrexate dose, mg/week, mean (SD) | 16.0 (4.4) | 16.2 (4.1) |
| Methotrexate dose, mg/week, median | 15.0 | 15.0 |
| No of previous DMARD (including methotrexate before study entry), mean (SD) | 1.9 (1.1) | 1.9 (1.0) |
| Oral steroid use, n (%) | 136 (49.1) | 135 (48.9) |
| Folic acid use, n (%) | 215 (77.6) | 224 (81.2) |
BMI, body mass index; DMARD, disease-modifying antirheumatic drug; DAS28–ESR, disease activity score based on 28 joints–erythrocyte sedimentation rate; HAQ–DI, health assessment questionnaire–disability index; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis; TCZ, tocilizumab.